217 related articles for article (PubMed ID: 31814710)
1. Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study.
Zhang J; Li A; Jiang Q; Zheng F; Zhu H
Drug Des Devel Ther; 2019; 13():3913-3918. PubMed ID: 31814710
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
[TBL] [Abstract][Full Text] [Related]
3. A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer.
Cui Q; Hu Y; Ma D; Liu H
Drug Des Devel Ther; 2021; 15():339-347. PubMed ID: 33536747
[TBL] [Abstract][Full Text] [Related]
4. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study.
Lan CY; Wang Y; Xiong Y; Li JD; Shen JX; Li YF; Zheng M; Zhang YN; Feng YL; Liu Q; Huang HQ; Huang X
Lancet Oncol; 2018 Sep; 19(9):1239-1246. PubMed ID: 30082170
[TBL] [Abstract][Full Text] [Related]
5. Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer.
Pan Z; Luo Z; He H; Chen Y; Zhao B; Yang Z; Li L
J Ovarian Res; 2023 Feb; 16(1):44. PubMed ID: 36823642
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study.
Chen W; Li Z; Zheng Z; Wu X
Cancer Med; 2020 Aug; 9(16):5899-5907. PubMed ID: 32627959
[TBL] [Abstract][Full Text] [Related]
7. Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial.
Wang T; Tang J; Yang H; Yin R; Zhang J; Zhou Q; Liu Z; Cao L; Li L; Huang Y; Jiang K; Wang W; She F; Guan N; Hou Z; Li N; Wu L
JAMA Oncol; 2022 Aug; 8(8):1169-1176. PubMed ID: 35771546
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of apatinib combined with liposomal doxorubicin or paclitaxel versus liposomal doxorubicin or paclitaxel monotherapy in patients with recurrent platinum-resistant ovarian cancer.
Yang H; Geng A; Wang Z; Wu C
J Obstet Gynaecol Res; 2023 Jun; 49(6):1611-1619. PubMed ID: 36988159
[TBL] [Abstract][Full Text] [Related]
9. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
O'Malley DM; Matulonis UA; Birrer MJ; Castro CM; Gilbert L; Vergote I; Martin LP; Mantia-Smaldone GM; Martin AG; Bratos R; Penson RT; Malek K; Moore KN
Gynecol Oncol; 2020 May; 157(2):379-385. PubMed ID: 32081463
[TBL] [Abstract][Full Text] [Related]
10. Successful maintenance therapy with apatinib inplatinum-resistant advanced ovarian cancer and literature review.
Jin M; Cai J; Wang X; Zhang T; Zhao Y
Cancer Biol Ther; 2018; 19(12):1088-1092. PubMed ID: 30110192
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
[TBL] [Abstract][Full Text] [Related]
12. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
[TBL] [Abstract][Full Text] [Related]
13. Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data.
Kato MK; Yunokawa M; Bun S; Shimoi T; Yonemori K; Miyasaka N; Kato T; Tamura K
J Cancer Res Clin Oncol; 2020 May; 146(5):1335-1341. PubMed ID: 32144536
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center.
Zhang G; Li XP; Liu BJ; Wang JL; Wang SJ; Cui H; Wei LH
Chin Med J (Engl); 2013 Dec; 126(23):4477-82. PubMed ID: 24286410
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
Oza A; Kaye S; Van Tornout J; Sessa C; Gore M; Naumann RW; Hirte H; Colombo N; Chen J; Gorla S; Poondru S; Singh M; Steinberg J; Yuen G; Banerjee S
Gynecol Oncol; 2018 May; 149(2):275-282. PubMed ID: 29454514
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer.
Conteduca V; Gurioli G; Rossi L; Scarpi E; Lolli C; Schepisi G; Farolfi A; De Lisi D; Gallà V; Burgio SL; Menna C; Amadori A; Losi L; Amadori D; Costi MP; De Giorgi U
BMC Cancer; 2018 Dec; 18(1):1267. PubMed ID: 30567527
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Apatinib Combined with Etoposide in Patients with Recurrent Platinum-resistant Epithelial Ovarian Cancer: A Retrospective Study.
Huang Q; Chu C; Tang J; Dai Z
J Cancer; 2020; 11(18):5353-5358. PubMed ID: 32742481
[No Abstract] [Full Text] [Related]
18. Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.
Tillmanns TD; Lowe MP; Walker MS; Stepanski EJ; Schwartzberg LS
Gynecol Oncol; 2013 Feb; 128(2):221-8. PubMed ID: 22960352
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab improves overall survival in platinum refractory ovarian cancer patients: A retrospective study.
Chikazawa K; Netsu S; Kuwata T; Konno R
Taiwan J Obstet Gynecol; 2018 Dec; 57(6):819-824. PubMed ID: 30545534
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of ovarian cancer with apatinib combined with chemotherapy: A case report.
Zhang M; Tian Z; Sun Y
Medicine (Baltimore); 2017 Nov; 96(45):e8570. PubMed ID: 29137078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
